These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 17703272

  • 1. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
    Dovio A, Generali D, Tampellini M, Berruti A, Tedoldi S, Torta M, Bonardi S, Tucci M, Allevi G, Aguggini S, Bottini A, Dogliotti L, Angeli A.
    Osteoporos Int; 2008 Jan; 19(1):113-7. PubMed ID: 17703272
    [Abstract] [Full Text] [Related]

  • 2. Variations in circulating osteoprotegerin and soluble RANKL during diurnal and menstrual cycles in young women.
    Shimizu M, Onoe Y, Mikumo M, Miyabara Y, Kuroda T, Yoshikata R, Ishitani K, Okano H, Ohta H.
    Horm Res; 2009 Jan; 71(5):285-9. PubMed ID: 19339793
    [Abstract] [Full Text] [Related]

  • 3. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women.
    Ostrowska Z, Kos-Kudła B, Marek B, Kajdaniuk D, Wołkowska-Pokrywa K.
    Postepy Hig Med Dosw (Online); 2011 Oct 11; 65():658-67. PubMed ID: 22100799
    [Abstract] [Full Text] [Related]

  • 4.  Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Wołkowska-Pokrywa K.
    Postepy Hig Med Dosw (Online); 2012 Sep 12; 66():655-62. PubMed ID: 23001207
    [Abstract] [Full Text] [Related]

  • 5. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Tsigris C, Kostaki MA, Perrea DN.
    J Endocrinol Invest; 2007 Oct 12; 30(9):762-6. PubMed ID: 17993768
    [Abstract] [Full Text] [Related]

  • 6. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.
    Bone; 2012 Jan 12; 50(1):156-60. PubMed ID: 22001124
    [Abstract] [Full Text] [Related]

  • 7. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.
    Ther Apher Dial; 2009 Feb 12; 13(1):49-55. PubMed ID: 19379170
    [Abstract] [Full Text] [Related]

  • 8. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
    Ostrowska Z, Świętochowska E, Marek B, Kajdaniuk D, Tyrpień-Golder K, Wołkowska-Pokrywa K, Damasiewicz-Bodzek A, Kos-Kudła B.
    Endokrynol Pol; 2014 Feb 12; 65(6):438-48. PubMed ID: 25554611
    [Abstract] [Full Text] [Related]

  • 9. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
    Acta Oncol; 2007 Feb 12; 46(2):221-9. PubMed ID: 17453373
    [Abstract] [Full Text] [Related]

  • 10. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A.
    Osteoporos Int; 2006 Feb 12; 17(5):693-703. PubMed ID: 16435076
    [Abstract] [Full Text] [Related]

  • 11. Assessment of the relationship between melatonin, hormones of the pituitary-ovarian, -thyroid and -adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Wołkowska-Pokrywa K, Szapska B.
    Postepy Hig Med Dosw (Online); 2013 May 20; 67():433-41. PubMed ID: 23752595
    [Abstract] [Full Text] [Related]

  • 12. Association between omentin-1, bone metabolism markers, and cytokines of the RANKL/RANK/OPG system in girls with anorexia nervosa.
    Gołąbek K, Ostrowska Z, Ziora K, Oświęcimska J, Świętochowska E, Marek B, Kajdaniuk D, Strzelczyk J, Kos-Kudła B.
    Endokrynol Pol; 2015 May 20; 66(6):514-20. PubMed ID: 26662650
    [Abstract] [Full Text] [Related]

  • 13. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Marek B, Świętochowska E, Kajdaniuk D, Strzelczyk J, Cieślicka A, Wołkowska-Pokrywa K, Kos-Kudła B.
    Endokrynol Pol; 2015 May 20; 66(4):313-21. PubMed ID: 26323468
    [Abstract] [Full Text] [Related]

  • 14. Osteoprotegerin and receptor activator of the nuclear factor kappa B ligand (RANKL) in healthy pubertal girls - relationships with physical growth and classical bone turnover markers.
    Kulik-Rechberger B, Kozłowska M.
    J Physiol Pharmacol; 2024 Feb 20; 75(1):. PubMed ID: 38583439
    [Abstract] [Full Text] [Related]

  • 15. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Feb 20; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 16. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 Feb 20; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 17. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
    Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P.
    Eur J Clin Invest; 2006 Aug 20; 36(8):566-73. PubMed ID: 16893379
    [Abstract] [Full Text] [Related]

  • 18. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
    Dovio A, Data V, Carignola R, Calzolari G, Vitetta R, Ventura M, Saba L, Severino A, Angeli A.
    J Rheumatol; 2008 Nov 20; 35(11):2206-13. PubMed ID: 18843778
    [Abstract] [Full Text] [Related]

  • 19. [Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease].
    Xu DR, Su C, Zou WY, Xu HR, Huang S, Li J, Luo SK.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr 20; 18(2):376-80. PubMed ID: 20416172
    [Abstract] [Full Text] [Related]

  • 20. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.
    Bone; 2006 Dec 20; 39(6):1352-60. PubMed ID: 16905375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.